CAMBRIDGE, Mass., Jan. 9, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that President and Chief Executive Officer, Thomas Hughes, Ph.D., is scheduled to present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference. The conference is being held January 13 - 16, 2014, at the Westin St. Francis Hotel in San Francisco, California. Zafgen is scheduled to present on Wednesday, January 15, 2014 at 7:30 A.M. PT.
About Zafgen, Inc.
Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients and related orphan indications by bringing beloranib, a first-in-class novel medicine, to market. Founded in 2005 as a virtual company, Zafgen brings together leading experts in obesity and metabolic disease to address the underserved and growing population of patients who are severely obese. Zafgen's singular focus is on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders including Prader-Willi syndrome and patients with hypothalamic obesity, including obesity resulting from surgical treatment of craniopharyngioma. The company is located in Cambridge, MA. For more information, visit zafgen.com.
SOURCE Zafgen, Inc.